Insulet Downgraded as Payments Stocks Win Analyst Favour

PODD took the sharpest hit in today's analyst round. Insulet Corporation was downgraded by consensus, with the average target price slashed to $204 from $235. That's a $31 drop. The insulin pump maker carries a $11.6bn market cap. Short interest sits at 6.6% of free float — modest, but the downgrade could attract more sellers.

Payments stocks told a different story. V, MA, and GPN all received target price upgrades. Visa's average target moved to $415. Mastercard hit $664. Global Payments climbed to $95.59. Analysts appear broadly positive on the payments sector after recent earnings.

LLY also won favour. Eli Lilly's consensus target rose to $1,283 from $1,277. The pharma giant's near-$1 trillion market cap remains a Wall Street favourite.

On the negative side, XYZ (Block, Inc.) saw its consensus target trimmed to $92.68 from $93. The cut is small but follows a broader pattern of caution on fintech names outside the traditional payments rails.

IFF saw multiple changes simultaneously. International Flavors & Fragrances drew mixed analyst calls, with the consensus holding at five buys and fourteen holds.